Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TK1 | P04183 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30163822 | 1.00 | IGF2R (0.36) | IGF2RCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL16084863 | 1.00 | IGF2R (0.36) | IGF2RCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL16154497 | 0.89 | ALDH1A1 (0.39) | IGF2RCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL16145424 | 0.89 | ALDH1A1 (0.39) | IGF2RCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL14704264 | 0.89 | ALDH1A1 (0.39) | IGF2RCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL30163856 | 0.89 | ALDH1A1 (0.39) | IGF2RCHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL24721233 | 0.88 | ALDH1A1 (0.41) | IGF2RTSHRTK1 | |
| SCHEMBL16084870 | 0.88 | ALDH1A1 (0.41) | IGF2RTSHRTK1 | |
| SCHEMBL16154509 | 0.88 | ALDH1A1 (0.41) | IGF2RTSHRTK1 | |
| SCHEMBL30465016 | 0.88 | ALDH1A1 (0.41) | IGF2RTSHRTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409650-A1 | COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA | HOLOCLARA INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220183291-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. | 2022-06-16 | — | — | US | disclosed |
| US-11019776-B2 | Compositions and methods for modulating immunity in plants | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190053451-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20160037741-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11019776-B2 | Compositions and methods for modulating immunity in plants | SLC11A2, IFNG, STING1 | IGF2R 3444/4885CHRM5 2595/4885CHRM1 3514/4885 |
| US-20160037741-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | SLC11A2, IFNG, STING1 | IGF2R 3444/4885CHRM5 2595/4885CHRM1 3514/4885 |
| US-20190053451-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | SLC11A2, IFNG, STING1 | IGF2R 3444/4885CHRM5 2595/4885CHRM1 3514/4885 |
| US-20220183291-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | IFNG, STING1, IRF3 | IGF2R 3429/4885CHRM5 2559/4885CHRM1 3342/4885 |
| US-20220409650-A1 | COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA | SI, FABP2, ALPI | IGF2R 2702/4885CHRM5 3540/4885CHRM1 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.